Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02516657 · ClinicalTrials.gov registry record · Phase 3
Liraglutide in Adolescents With Type 1 Diabetes
A Phase 3 study of Type 1 Diabetes, sponsored by University at Buffalo.
- Completed
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT02516657 is a Phase 3 study of Type 1 Diabetes that has completed, run by University at Buffalo. The registered enrollment target is 5 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02516657, a Phase 3 study of Type 1 Diabetes, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to study the effect of a liraglutide, a glucagon-like peptide agonist, on post-meal blood glucose concentrations, glucagon levels, mean weekly blood sugars, and insulin doses in adolescents with Type 1 diabetes. Type 1 diabetes is an autoimmune disease that is usually diagnosed before the age of 20. Individuals with this disease are completely dependent on insulin for survival. While significant advances have been made in technological support for improving diabetes control, insulin remains the only effective treatment for Type 1 diabetes. Liraglutide is a long-acting glucagon-like peptide-1 analog. This drug is approved for the treatment of Type 2 diabetes in adults. This study will test the effect of liraglutide on blood sugar control in adolescents with Type 1 diabetes.
Conditions Studied
Interventions
- DRUG Liraglutide
Study Locations (1)
New York
- UBMD Pediatrics, Division of Pediatric Endocrinology - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-05 |
| Est. Completion | 2023-08-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02516657
The ClinicalTrials.gov registry entry for NCT02516657 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Liraglutide is the first listed.
NCT02516657 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02516657 about?
NCT02516657 is a clinical study titled "Liraglutide in Adolescents With Type 1 Diabetes". The purpose of this study is to study the effect of a liraglutide, a glucagon-like peptide agonist, on post-meal blood glucose concentrations, glucagon levels, mean weekly blood sugars, and insulin doses in adolescents with Type 1 diabetes. Type 1 diabetes is an autoimmune disease that is usually di...
What is the current status of trial NCT02516657?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2012-05. Estimated completion is 2023-08-03.
What conditions does trial NCT02516657 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT02516657?
The interventions under investigation include: Liraglutide (DRUG).
Who is sponsoring clinical trial NCT02516657?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02516657 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
RECRUITING · Phase 3
-
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients
ACTIVE NOT RECRUITING · Phase 3
-
Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes
COMPLETED · Phase 3
-
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.